Clinical Trials Directory

Trials / Completed

CompletedNCT03788577

Impact of Oligonol to Cardiometabolic Risk and Muscular Health

Impact of Oligonol to Cardiometabolic Risk and Muscular Health: a Randomized Controlled Trial

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
120 (actual)
Sponsor
National Yang Ming Chiao Tung University · Academic / Other
Sex
All
Age
50 Years
Healthy volunteers
Not accepted

Summary

This project will mainly focus on Middle and old-aged adults, and examine whether Cardiovascular and metabolic risks can be reduced. In the meanwhile, this project will develop strategies for improving muscle loss , muscle strength decline, and the quality life of the elderly.

Detailed description

Cardiovascular diseases are common among the elder. However, previous researches mainly focus on observational research or small scale clinical trial, and the subjects are mainly youth. Therefore, this project hope to understand whether Oligonol can reduce Cardiovascular and metabolic risks among senior adults. Consequently,improve muscle loss muscle strength decline, quality of old adults life. This project design may potentially develop new strategies for curing Sarcopenia as well.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTOligonol intakeMajor intervention of Oligonol component , as suggested Oligonol safe dose for adults is 200mg per day.
DIETARY_SUPPLEMENTPlaceboPlacebo

Timeline

Start date
2018-12-04
Primary completion
2020-04-01
Completion
2020-04-01
First posted
2018-12-27
Last updated
2023-04-14

Locations

1 site across 1 country: Taiwan

Source: ClinicalTrials.gov record NCT03788577. Inclusion in this directory is not an endorsement.